Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-04-15 21:49:26 ET · period of report 2026-04-13 · accession 0001789617-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-15 21:49 | 2026-04-13 | TVTX | Heerma Peter | Chief COMMERCIAL Off | A - Grant | $0.00 | +14.0K | 145.8K | +11% | $0 | |
| 2026-04-15 21:49 | 2026-04-14 | TVTX | Heerma Peter | Chief COMMERCIAL Off | S - Sale | $41.93 | -7,215 | 138.6K | -5% | -$302.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-13 | A | A | 14,000 | $0.00 | 145,823 | D | — | — | (F1) On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS. |
| 2 | Common | Common Stock | 2026-04-14 | S | D | 7,215 | $41.93 | 138,608 | D | — | — | (F2) Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. |